Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOT101 + Cetuximab in RAS Wild-Type Colorectal Cancer
NCT05619172Phase 2Terminated
- Sponsor
- SOTIO Biotech
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, open-label trial of nanrilkefusp alfa in colorectal cancer (CRC) (2 arms), sponsored by SOTIO Biotech. Primary endpoint: Objective Response Rate. Started Dec 2022; status: terminated.
02
Drugs
nanrilkefusp alfa
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05619172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619172.